Financial outcomes for the fourth quarter of 2024 revealed by Eli Lilly, featuring significant points and stock fluctuations.
In a significant development for the pharmaceutical industry, Eli Lilly has announced its fourth-quarter 2024 financial results, with the company's blockbuster drugs Mounjaro and Zepbound playing a pivotal role in driving revenue growth.
The financial results, published by the company, reveal a 45% increase in revenue, reaching $13.53 billion. This impressive figure was largely attributed to the sales of Mounjaro and Zepbound, which contributed $3.53 billion and $1.91 billion respectively during this period.
Mounjaro and Zepbound, both containing the active ingredient tirzepatide, are making waves in the treatment of various conditions. Mounjaro recently received FDA approval for treating moderate-to-severe obstructive sleep apnea in adults with obesity, while Zepbound has been approved for moderately to severely active Crohn's disease in the U.S., as Omvoh also announced its approval for the same indication.
Eli Lilly's adjusted EPS of $5.32 also exceeded analyst expectations, further underscoring the company's financial strength. The company reported EPS of $4.88 per share on a GAAP basis.
However, the report did not provide any guidance for 2025, leaving investors and analysts eagerly awaiting further insights into the company's future plans and financial projections.
As the competition in the pharmaceutical industry continues to intensify, Eli Lilly's Q4 2024 financial results serve as a testament to the company's strategic focus and the potential of its innovative drugs. With Mounjaro and Zepbound leading the charge, Eli Lilly is poised to continue making significant strides in the treatment of various conditions.
